Arcturus Announces Launch of 12-Week Cystic Fibrosis Study in 2026, Facing Cost Management and KOSTAIVE BLA Delays
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy ARCT?
Source: SeekingAlpha
Management Insights: CEO Joseph Payne reported positive interim Phase II data for ARCT-032, an mRNA therapeutic for cystic fibrosis, and ARCT-810 for OTC deficiency, while also noting the indefinite delay of the KOSTAIVE COVID-19 vaccine's US BLA filing due to regulatory changes.
Financial Performance: CFO Andrew Sassine highlighted a significant revenue decline for Q3 2025, with total revenues of $17.2 million, and a net loss of approximately $13.5 million, while emphasizing the company's strong financial position with a cash runway extended into 2028.
Future Outlook: The company plans to initiate a 12-week study for ARCT-032 in the first half of 2026 and is preparing for regulatory meetings regarding pivotal trials for both CF and OTC programs, focusing on safety and efficacy data.
Risks and Concerns: Management acknowledged challenges due to sudden FDA regulatory changes affecting KOSTAIVE, alongside the need for further regulatory alignment for both therapeutic programs, while maintaining a focus on cost control and resource allocation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARCT
Wall Street analysts forecast ARCT stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 8.900
Low
7.00
Averages
14.00
High
20.00
Current: 8.900
Low
7.00
Averages
14.00
High
20.00
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcturus Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: Arcturus initiated its 12-week Phase II trial for ARCT-032 in Q1 2026, having surpassed one month of dosing, which signifies steady advancement in its rare disease pipeline and is expected to provide crucial support for future clinical data collection.
- Strong Financial Position: As of March 31, 2026, the company reported $213.4 million in cash and cash equivalents, a decrease from $232.8 million on December 31, 2025, primarily due to reduced revenue from CSL collaborations, reflecting a strategic shift towards rare disease clinical programs.
- R&D Expense Control: Quarterly R&D expenses decreased by $13.4 million year-over-year, driven by lower manufacturing costs associated with LUNAR-COVID and BARDA, although increased costs related to LUNAR-OTC partially offset these reductions, demonstrating effective cost management by the company.
- Clear Regulatory Path: Following a meeting with the FDA, management received clear regulatory direction for ARCT-810, with an end-of-Phase II meeting planned for the second half of 2026, indicating a strategic focus on pediatric studies is becoming increasingly defined.
See More
Arcturus Therapeutics Q1 Earnings Analysis
- Earnings Performance: Arcturus Therapeutics reported a Q1 GAAP EPS of -$0.95, beating expectations by $0.04, yet revenue plummeted to $2.06M, down 93% year-over-year, missing estimates by $4.81M, indicating significant operational challenges.
- Cash Position: As of March 31, 2026, the company held $213.4 million in cash and equivalents, down from $232.8 million on December 31, 2025, reflecting pressure on cash management that could impact future R&D investments.
- Market Reaction: The downgrade to a 'Hold' rating due to a shift in the CF program's population focus has diminished market confidence in Arcturus's growth potential, likely putting downward pressure on its stock price.
- Future Outlook: The company plans to launch a 12-week Phase II CF trial in 2026 and anticipates regulatory clarity for ARCT-810, presenting potential new growth opportunities despite the current challenges.
See More
Arcturus Therapeutics Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Arcturus Therapeutics (ARCT) is set to release its Q1 earnings on May 7 after market close, with consensus EPS estimate at -$1.01 and revenue estimate at $6.87 million, reflecting a significant 76.6% year-over-year decline, indicating substantial challenges ahead for the company.
- Historical Performance: Over the past year, ARCT has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, suggesting a degree of financial stability despite current pressures, which may influence investor sentiment.
- Estimate Adjustments: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced one upward and one downward revision, highlighting market uncertainty regarding the company's future performance.
- Clinical Trial Progress: Arcturus is advancing a 12-week Phase II clinical trial for cystic fibrosis (CF) and expects regulatory clarity for ARCT-810 in 2026, which could provide new growth momentum for the company moving forward.
See More
Transformation of Value in Biotechnology Sector
- Value Shift: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset rather than just research expenditure, reinforced by fair-value accounting under U.S. GAAP that allows companies to reflect clinical advancements and commercialization timing on their balance sheets.
- Investment Opportunities in Clinical Assets: Institutional investors are increasingly recognizing the investment value of clinical-stage biotech assets, even in the absence of current revenue, as Oncotelic Therapeutics exemplifies how scientific progress can directly influence financial positioning, significantly enhancing enterprise valuation through its diversified pipeline and 45% stake in GMP Bio.
- Clinical Development Drives Valuation: As drug candidates advance through clinical development, their value significantly increases due to rising probabilities of success and proximity to commercialization, particularly for late-stage assets nearing regulatory approval, which tend to command a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and Manufacturing Convergence: AI-driven drug development and GMP-compliant manufacturing platforms are accelerating timelines and improving scalability across the biotech industry, with Oncotelic Therapeutics demonstrating how to integrate oncology drug development with AI platforms, thereby linking scientific advancement with financial valuation and positioning the company favorably in the rapidly evolving biotech landscape.
See More
Biotechnology Sector Undergoes Value Transformation
- Value Transformation Trend: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset, particularly as drug candidates approach commercialization, significantly enhancing companies' balance sheet values.
- Fair Value Accounting Implementation: The adoption of fair-value accounting under U.S. GAAP allows life sciences companies to incorporate clinical progress, probability of success, and commercialization timing into financial reporting, thereby increasing transparency and attracting institutional investors to clinical-stage biotech assets.
- Clinical Progress Drives Valuation: As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization, with late-stage assets commanding a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and GMP Manufacturing Convergence: The integration of AI-driven drug development and GMP-compliant manufacturing accelerates timelines and enhances scalability across the biotech industry, improving clinical development efficiency and market readiness, further driving the alignment of scientific progress with financial valuation.
See More
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
Arcturus Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: Arcturus initiated its 12-week Phase II trial for ARCT-032 in Q1 2026, having surpassed one month of dosing, which signifies steady advancement in its rare disease pipeline and is expected to provide crucial support for future clinical data collection.
- Strong Financial Position: As of March 31, 2026, the company reported $213.4 million in cash and cash equivalents, a decrease from $232.8 million on December 31, 2025, primarily due to reduced revenue from CSL collaborations, reflecting a strategic shift towards rare disease clinical programs.
- R&D Expense Control: Quarterly R&D expenses decreased by $13.4 million year-over-year, driven by lower manufacturing costs associated with LUNAR-COVID and BARDA, although increased costs related to LUNAR-OTC partially offset these reductions, demonstrating effective cost management by the company.
- Clear Regulatory Path: Following a meeting with the FDA, management received clear regulatory direction for ARCT-810, with an end-of-Phase II meeting planned for the second half of 2026, indicating a strategic focus on pediatric studies is becoming increasingly defined.
See More
Arcturus Therapeutics Q1 Earnings Analysis
- Earnings Performance: Arcturus Therapeutics reported a Q1 GAAP EPS of -$0.95, beating expectations by $0.04, yet revenue plummeted to $2.06M, down 93% year-over-year, missing estimates by $4.81M, indicating significant operational challenges.
- Cash Position: As of March 31, 2026, the company held $213.4 million in cash and equivalents, down from $232.8 million on December 31, 2025, reflecting pressure on cash management that could impact future R&D investments.
- Market Reaction: The downgrade to a 'Hold' rating due to a shift in the CF program's population focus has diminished market confidence in Arcturus's growth potential, likely putting downward pressure on its stock price.
- Future Outlook: The company plans to launch a 12-week Phase II CF trial in 2026 and anticipates regulatory clarity for ARCT-810, presenting potential new growth opportunities despite the current challenges.
See More
Arcturus Therapeutics Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Arcturus Therapeutics (ARCT) is set to release its Q1 earnings on May 7 after market close, with consensus EPS estimate at -$1.01 and revenue estimate at $6.87 million, reflecting a significant 76.6% year-over-year decline, indicating substantial challenges ahead for the company.
- Historical Performance: Over the past year, ARCT has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, suggesting a degree of financial stability despite current pressures, which may influence investor sentiment.
- Estimate Adjustments: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced one upward and one downward revision, highlighting market uncertainty regarding the company's future performance.
- Clinical Trial Progress: Arcturus is advancing a 12-week Phase II clinical trial for cystic fibrosis (CF) and expects regulatory clarity for ARCT-810 in 2026, which could provide new growth momentum for the company moving forward.
See More
Transformation of Value in Biotechnology Sector
- Value Shift: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset rather than just research expenditure, reinforced by fair-value accounting under U.S. GAAP that allows companies to reflect clinical advancements and commercialization timing on their balance sheets.
- Investment Opportunities in Clinical Assets: Institutional investors are increasingly recognizing the investment value of clinical-stage biotech assets, even in the absence of current revenue, as Oncotelic Therapeutics exemplifies how scientific progress can directly influence financial positioning, significantly enhancing enterprise valuation through its diversified pipeline and 45% stake in GMP Bio.
- Clinical Development Drives Valuation: As drug candidates advance through clinical development, their value significantly increases due to rising probabilities of success and proximity to commercialization, particularly for late-stage assets nearing regulatory approval, which tend to command a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and Manufacturing Convergence: AI-driven drug development and GMP-compliant manufacturing platforms are accelerating timelines and improving scalability across the biotech industry, with Oncotelic Therapeutics demonstrating how to integrate oncology drug development with AI platforms, thereby linking scientific advancement with financial valuation and positioning the company favorably in the rapidly evolving biotech landscape.
See More
Biotechnology Sector Undergoes Value Transformation
- Value Transformation Trend: The biotechnology sector is undergoing a profound transformation where scientific progress is increasingly viewed as a measurable financial asset, particularly as drug candidates approach commercialization, significantly enhancing companies' balance sheet values.
- Fair Value Accounting Implementation: The adoption of fair-value accounting under U.S. GAAP allows life sciences companies to incorporate clinical progress, probability of success, and commercialization timing into financial reporting, thereby increasing transparency and attracting institutional investors to clinical-stage biotech assets.
- Clinical Progress Drives Valuation: As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization, with late-stage assets commanding a disproportionate share of enterprise value, reflecting investors' focus on pipeline asset maturity.
- AI and GMP Manufacturing Convergence: The integration of AI-driven drug development and GMP-compliant manufacturing accelerates timelines and enhances scalability across the biotech industry, improving clinical development efficiency and market readiness, further driving the alignment of scientific progress with financial valuation.
See More
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
